诺华支付6.5亿美元用于百济神州抗PD-1药物tislelizumab的海外使用权

2021-01-12 Allan MedSci原创

诺华公司本周一宣布,诺华已与百济神州签署了一项战略协议,已获得中国以外的几个主要市场的tislelizumab销售权。

诺华公司本周一宣布,诺华已与百济神州签署了一项战略协议,已获得中国以外的几个主要市场的tislelizumab销售权。作为交易的一部分,诺华将向百济神州支付6.5亿美元的前期现金付款,百济神州还有望在达到监管里程碑后获得最高13亿美元的现金付款。

具体而言,该协议赋予诺华在美国、欧盟、英国、挪威、瑞士、冰岛、列支敦士登、俄罗斯和日本的tislelizumab开发和营销权。同时,百济神州将在中国中保留tislelizumab的开发和营销权。百济神州还提交了申请,寻求中国监管部门批准该药物用于晚期鳞状和非鳞状非小细胞肺癌(NSCLC)以及不可切除的肝细胞癌(HCC)。

诺华和百济神州表示,目前已在15项临床试验中对tislelizumab进行了评估,涉及7700多例各种肿瘤患者,包括NSCLC、HCC、食道鳞状细胞癌、胃癌和鼻咽癌,预计2021年将在中国以外首次提交监管文件。

 

原始出处:

https://www.firstwordpharma.com/node/1790474?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1912512, encodeId=63fe1912512b1, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Sep 17 21:30:05 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748955, encodeId=f4c51e4895512, content=<a href='/topic/show?id=e4d6655811a' target=_blank style='color:#2F92EE;'>#海外#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65581, encryptionId=e4d6655811a, topicName=海外)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82fd36209189, createdName=lishizhe, createdTime=Wed Mar 31 04:30:05 CST 2021, time=2021-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920361, encodeId=5b1792036169, content=神州好药, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ZBAFYNOLbJf2mpwWDiciaJZxm06o0jHmQNOQ4ImNu3z1sAVNlrEc4KiacxicZTOjoZ2GwHRyZAZEyj26XKicODKYf7A/132, createdBy=ba375247513, createdName=鹏儿, createdTime=Wed Jan 27 18:51:38 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282824, encodeId=2e4212828243b, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Thu Jan 14 12:30:05 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345038, encodeId=d8d71345038cb, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Thu Jan 14 12:30:05 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916182, encodeId=7c87916182c3, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL6WtEGIUW7S4y7deE788VzMsq6otNLXEGN9TMqNva75ExPoZsyIlpZibuHYALoBYWED7lY6oUE3UQ/132, createdBy=14875307258, createdName=margery, createdTime=Wed Jan 13 10:57:14 CST 2021, time=2021-01-13, status=1, ipAttribution=)]
    2021-09-17 snf701207
  2. [GetPortalCommentsPageByObjectIdResponse(id=1912512, encodeId=63fe1912512b1, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Sep 17 21:30:05 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748955, encodeId=f4c51e4895512, content=<a href='/topic/show?id=e4d6655811a' target=_blank style='color:#2F92EE;'>#海外#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65581, encryptionId=e4d6655811a, topicName=海外)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82fd36209189, createdName=lishizhe, createdTime=Wed Mar 31 04:30:05 CST 2021, time=2021-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920361, encodeId=5b1792036169, content=神州好药, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ZBAFYNOLbJf2mpwWDiciaJZxm06o0jHmQNOQ4ImNu3z1sAVNlrEc4KiacxicZTOjoZ2GwHRyZAZEyj26XKicODKYf7A/132, createdBy=ba375247513, createdName=鹏儿, createdTime=Wed Jan 27 18:51:38 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282824, encodeId=2e4212828243b, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Thu Jan 14 12:30:05 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345038, encodeId=d8d71345038cb, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Thu Jan 14 12:30:05 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916182, encodeId=7c87916182c3, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL6WtEGIUW7S4y7deE788VzMsq6otNLXEGN9TMqNva75ExPoZsyIlpZibuHYALoBYWED7lY6oUE3UQ/132, createdBy=14875307258, createdName=margery, createdTime=Wed Jan 13 10:57:14 CST 2021, time=2021-01-13, status=1, ipAttribution=)]
    2021-03-31 lishizhe
  3. [GetPortalCommentsPageByObjectIdResponse(id=1912512, encodeId=63fe1912512b1, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Sep 17 21:30:05 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748955, encodeId=f4c51e4895512, content=<a href='/topic/show?id=e4d6655811a' target=_blank style='color:#2F92EE;'>#海外#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65581, encryptionId=e4d6655811a, topicName=海外)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82fd36209189, createdName=lishizhe, createdTime=Wed Mar 31 04:30:05 CST 2021, time=2021-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920361, encodeId=5b1792036169, content=神州好药, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ZBAFYNOLbJf2mpwWDiciaJZxm06o0jHmQNOQ4ImNu3z1sAVNlrEc4KiacxicZTOjoZ2GwHRyZAZEyj26XKicODKYf7A/132, createdBy=ba375247513, createdName=鹏儿, createdTime=Wed Jan 27 18:51:38 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282824, encodeId=2e4212828243b, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Thu Jan 14 12:30:05 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345038, encodeId=d8d71345038cb, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Thu Jan 14 12:30:05 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916182, encodeId=7c87916182c3, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL6WtEGIUW7S4y7deE788VzMsq6otNLXEGN9TMqNva75ExPoZsyIlpZibuHYALoBYWED7lY6oUE3UQ/132, createdBy=14875307258, createdName=margery, createdTime=Wed Jan 13 10:57:14 CST 2021, time=2021-01-13, status=1, ipAttribution=)]
    2021-01-27 鹏儿

    神州好药

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1912512, encodeId=63fe1912512b1, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Sep 17 21:30:05 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748955, encodeId=f4c51e4895512, content=<a href='/topic/show?id=e4d6655811a' target=_blank style='color:#2F92EE;'>#海外#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65581, encryptionId=e4d6655811a, topicName=海外)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82fd36209189, createdName=lishizhe, createdTime=Wed Mar 31 04:30:05 CST 2021, time=2021-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920361, encodeId=5b1792036169, content=神州好药, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ZBAFYNOLbJf2mpwWDiciaJZxm06o0jHmQNOQ4ImNu3z1sAVNlrEc4KiacxicZTOjoZ2GwHRyZAZEyj26XKicODKYf7A/132, createdBy=ba375247513, createdName=鹏儿, createdTime=Wed Jan 27 18:51:38 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282824, encodeId=2e4212828243b, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Thu Jan 14 12:30:05 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345038, encodeId=d8d71345038cb, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Thu Jan 14 12:30:05 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916182, encodeId=7c87916182c3, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL6WtEGIUW7S4y7deE788VzMsq6otNLXEGN9TMqNva75ExPoZsyIlpZibuHYALoBYWED7lY6oUE3UQ/132, createdBy=14875307258, createdName=margery, createdTime=Wed Jan 13 10:57:14 CST 2021, time=2021-01-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1912512, encodeId=63fe1912512b1, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Sep 17 21:30:05 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748955, encodeId=f4c51e4895512, content=<a href='/topic/show?id=e4d6655811a' target=_blank style='color:#2F92EE;'>#海外#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65581, encryptionId=e4d6655811a, topicName=海外)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82fd36209189, createdName=lishizhe, createdTime=Wed Mar 31 04:30:05 CST 2021, time=2021-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920361, encodeId=5b1792036169, content=神州好药, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ZBAFYNOLbJf2mpwWDiciaJZxm06o0jHmQNOQ4ImNu3z1sAVNlrEc4KiacxicZTOjoZ2GwHRyZAZEyj26XKicODKYf7A/132, createdBy=ba375247513, createdName=鹏儿, createdTime=Wed Jan 27 18:51:38 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282824, encodeId=2e4212828243b, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Thu Jan 14 12:30:05 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345038, encodeId=d8d71345038cb, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Thu Jan 14 12:30:05 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916182, encodeId=7c87916182c3, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL6WtEGIUW7S4y7deE788VzMsq6otNLXEGN9TMqNva75ExPoZsyIlpZibuHYALoBYWED7lY6oUE3UQ/132, createdBy=14875307258, createdName=margery, createdTime=Wed Jan 13 10:57:14 CST 2021, time=2021-01-13, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1912512, encodeId=63fe1912512b1, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Sep 17 21:30:05 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748955, encodeId=f4c51e4895512, content=<a href='/topic/show?id=e4d6655811a' target=_blank style='color:#2F92EE;'>#海外#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65581, encryptionId=e4d6655811a, topicName=海外)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82fd36209189, createdName=lishizhe, createdTime=Wed Mar 31 04:30:05 CST 2021, time=2021-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920361, encodeId=5b1792036169, content=神州好药, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ZBAFYNOLbJf2mpwWDiciaJZxm06o0jHmQNOQ4ImNu3z1sAVNlrEc4KiacxicZTOjoZ2GwHRyZAZEyj26XKicODKYf7A/132, createdBy=ba375247513, createdName=鹏儿, createdTime=Wed Jan 27 18:51:38 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282824, encodeId=2e4212828243b, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Thu Jan 14 12:30:05 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345038, encodeId=d8d71345038cb, content=<a href='/topic/show?id=cf721640495' target=_blank style='color:#2F92EE;'>#SLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16404, encryptionId=cf721640495, topicName=SLE)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/kbRUeosenzlejlNGWXdWjSYhBKL1QYGQwfehJOkMXHiavh5wl7pKeju5Kcxdvr50ic6FWML3x6NMCxhG1bOaVjyA/132, createdBy=20872500216, createdName=ms4657536712156177, createdTime=Thu Jan 14 12:30:05 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916182, encodeId=7c87916182c3, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL6WtEGIUW7S4y7deE788VzMsq6otNLXEGN9TMqNva75ExPoZsyIlpZibuHYALoBYWED7lY6oUE3UQ/132, createdBy=14875307258, createdName=margery, createdTime=Wed Jan 13 10:57:14 CST 2021, time=2021-01-13, status=1, ipAttribution=)]
    2021-01-13 margery

    学习

    0

相关资讯

美国FDA延迟批准诺华的siRNA药物inclisiran

高脂血症(Hyperlipidaemia)是指血液脂蛋白异常升高的情况。血脂的主要成分有胆固醇、三酸甘油酯与磷脂类。

英国首位患者在NHS内接受诺华的Luxturna基因疗法治疗先天性黑蒙病

英国国家医疗服务体系(NHS)表示,作为其长期计划的一部分,诺华公司的Luxturna(voretigene neparvovec)基因疗法将用于首位遗传性视网膜疾病-莱伯先天性黑蒙病(LCA)患者以恢复视力。

2020 Q1各大药企收入排名,强生,罗氏,诺华,默沙东,辉瑞,礼来,阿斯利康......

4月份,强生,礼来,GSK,辉瑞、诺华、默沙东相继发布了2020年第一季度财报。在疫情的笼罩之下,今年注定是不平凡的一年。而对于跨国药企而言,其开年业绩就上演了“王座更迭”的戏

药代备案制后,诺华、罗氏调整团队

近日,诺华发布全员邮件,自2020年12月1日起,心血管事业部与基础疾病事业部合并成为全新的心血管、肾科和代谢事业部(CardiovascularRenal & Metabolism Unit

诺华的抗血管内皮生长因子(VEGF)单抗Beovu获欧盟批准,用于治疗年龄相关的湿性黄斑变性

诺华公司宣布其抗血管内皮生长因子(VEGF)单抗Beovu(brolucizumab)已获得欧洲委员会(EC)的批准,用于治疗与年龄相关的湿性黄斑变性(AMD)。

C3肾小球病的治疗或迎重大突破!Iptacopan显示出希望

在一项II期研究中,诺华的肾脏疾病候选药物iptacopan的显示出治疗C3肾小球病的希望。

拓展阅读

百济神州的tislelizumab在中国再次获得批准

与化疗相比,tislelizumab 可将 ESCC 患者的死亡风险降低 30%。

Boston Immune与百济神州签订**选择权和许可协议,以开发新型TNFR2抗体

波士顿免疫技术和治疗公司(Boston Immune)今天宣布,已和百济神州签订独家选择权和许可协议,旨在开发和商业化Boston Immune的创新性肿瘤坏死因子(TNF)受体2(TNFR2)抗体。

百济神州PD-1单抗Tislelizumab治疗肝细胞癌的新药申请被NMPA接受,以及Tislelizumab抗肿瘤临床研究汇总

“世界上一半的肝癌患者都居住在中国,医疗需求仍未得到满足。”